We believe that our work provides useful information about certain effector and regulatory molecules, signalling pathways and biological processes that, in the context of the interaction in the TME between the tumour cell and CAFs, could be relevant as inducers of the resistance that the HER2-positive breast cancer cell develops towards HER2-targeted therapy. This evidence concerns the gene ERBB2 and neoplasm.